Equities News

According to Al Jazeera, Israeli air attacks in southern Lebanon killed civilians and emergency personnel while negotiation talks took place in Pakistan.

As demands for de-escalation increased worldwide, Indonesia reportedly welcomed the negotiations as an "encouraging" step toward a peaceful, long-lasting settlement.

The stock gained over 3% this week, marking its second consecutive week in the green.

The EV maker’s website in the Netherlands shows that customers can either buy a monthly subscription for the technology for €99 a month or make a one time purchase for €7,500.

The stock opened at $8.81, traded as high as $9.01, but sold off sharply to close at an all-time low of $8.58.

In an interview with Stocktwits, Yuri Khodjamirian said Artemis II is shifting the lunar economy towards newer players like Rocket Lab, AST SpaceMobile, and Intuitive Machines, poised to develop faster than legacy names.

Earlier on Friday, the FDA refused to approve Replimune’s investigational melanoma drug RP1, which was a likely contender for Iovance’s Amtagvi.

Earlier this week, Plus Therapeutics said that the FDA has granted Orphan Drug Designation to its experimental drug REYOBIQ for the treatment of pediatric malignant gliomas.

Earlier this week, Deutsche Bank downgraded the stock to ‘Hold’ from ‘Buy’ while maintaining a $128 price target

Space stocks, including Rocket Lab, AST SpaceMobile, Planet Labs, and Intuitive Machines, have rallied alongside the Artemis II mission.

According to a Reuters report, Commvault Systems is working with Goldman Sachs to consider options after receiving takeover interest from multiple potential buyers.

Anthropic’s Mythos can independently detect software weaknesses, sparking doubts about the relevance of current edge-based security systems.

In a Stocktwits interview, TEMA ETFs CIO Yuri Khodjamirian, who also manages the new NASA ETF, said its launch alongside Artemis II was “fortuitous” and “a coincidence.”

During an interview with CNBC, CoreWeave CEO Michael Intrator highlighted that the priority for CoreWeave is to scale up its operations right now, which can be expensive.

Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating after the company posted the interim results for its ovarian cancer drug.

On Friday, the FDA said that the revised application does not alter its initial conclusion of the ineffectiveness of the trials conducted by Replimune.

Earlier this week, “The Big Short” investor Michael Burry stated in a now-deleted post on X that Anthropic is eating Palantir’s lunch.

Gemini’s stock tumbled in morning trade after a more than 50% cut in its price target by Morgan Stanley.

The surge in NBIS stock comes amid a slew of developments, including the construction of a new 310-megawatt AI factory in Finland and an expanding partnership with Nvidia.

Citron Research argued that Applied Optoelectronics’ roughly $3.5 billion increase in market value was fueled by short-term hype following a recent announcement.

The company announced a $13 million offering at $7.50 per unit, compared with the stock’s Thursday closing price of $13.91.

Ives reaffirmed his ‘Outperform’ rating on the stock and held steady with a $230 price target, suggesting about 77% upside from Thursday’s closing level.

B. Riley upgraded MacroGenics to ’Buy’ from ‘Neutral’ with a $9 price target, according to The Fly.

Snapchat’s unit, Specs, has partnered with Qualcomm to power its Spectacles augmented reality glasses with Snapdragon chips

Consumer price index (CPI) rose 0.9% in March on a seasonally adjusted basis, after rising 0.3% in February.

Piper Sandler cut its price target for the NKE stock for the second time this month, after the firm trimmed its price target to $60 from $75 following Nike’s third-quarter results.

A report stated that Indian pharmaceutical giant Sun Pharma is expected to submit a $12 billion binding offer for the company.

TD Cowen said it expects Bitcoin to reach $140,000 and for Ethereum’s price to hit $3,650 by year-end.

The FDA is expected to announce its decision on Filspari, a drug to treat focal segmental glomerulosclerosis, a type of kidney ailment.

While retail sentiment on Stocktwits remained in ‘bearish’ territory for Coinbase, sentiment around Galaxy Digital jumped to ‘extremely bullish’ from the ‘neutral’ zone.

The new safety recall adds to a tough year marked by weak deliveries and multiple quality-related issues.

President Donald Trump criticized Iran late night on Thursday for reportedly collecting toll from tankers trying to pass through the Strait of Hormuz.

TSLA is on pace for its worst weekly decline in nearly seven months, extending a streak of eight consecutive weekly losses.

REPL stock is heading for its worst weekly loss in nearly seven months ahead of the FDA decision on RP1.

U.S.-listed shares of Telix Pharmaceuticals rose after the FDA accepted its NDA application for a brain cancer imaging agent.

Investors remain cautious as large luxury EV SUVs face weaker demand than that of hybrid and extended-range rivals such as the Aito M9 and the Li Auto L9.

ArcelorMittal, the world's second-largest steelmaker, is supplying the steel for the White House, according to a New York Times report, with the material produced in Europe.

SpaceX's IPO momentum is lifting the broader space economy, with strong inflows into ETFs and gains in sector-specific stocks.

UBS expects DDR prices to rise 37% and NAND prices 40% in Q2, boosting the AI memory demand outlook.

Oil prices stayed elevated, with WTI above $97 per barrel and Brent closing at $95.92.

Reuters reported earlier today, citing people familiar with the matter, that Tesla is developing an all-new smaller, cheaper electric SUV, signalling a return in focus on the company’s EV business.

IOVA stock closed in the green for the past three days and recorded its best single-day gain on Thursday since late February.

The company said that the layoffs, in addition to process changes and vendor cost optimization, is expected to generate $25-30 million in recurring annualized operating cost savings in 2027.

According to a report from the Wall Street Journal on Thursday, GSK asked the FDA to pull its application for leucovorin calcium because it no longer markets the medicine.

Coindesk reported that potential buyers are evaluating an acquisition of parts of the crypto exchange.

The quarter marked the final impact from last year’s sale of much of the healthcare business, which had previously influenced sales and profit comparisons.

JPMorgan Chase raised its price target on the stock to $950 from $565 and kept an “Overweight” rating on the stock.

In an op-ed in The Wall Street Journal, Scott Bessent said the legislation is needed to bring blockchain developers and firms back from overseas markets.

Trading of Actelis’ shares is expected to be suspended on April 10, after the company failed to meet Nasdaq’s minimum bid price requirement.

The FTC alleged that StubHub failed to display the full pricing of tickets to buyers.